Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer

October 2nd 2013

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.

Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer

September 30th 2013

Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.

OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC

September 29th 2013

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

Personalized Medicine in Colorectal Cancer

September 29th 2013

Novel Therapies in Development for mCRC

September 29th 2013

Second-Line and Salvage Treatment of mCRC

September 29th 2013

Antiangiogenic Therapy in Metastatic Colorectal Cancer

September 29th 2013

Maintenance Therapy in Metastatic Colorectal Cancer

September 29th 2013

Case Study: Borderline Resectable mCRC

September 29th 2013

Predictive Value of RAS Mutations in mCRC

September 29th 2013

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

September 29th 2013

EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013

TRIBE Trial: First-Line Treatment of mCRC

September 29th 2013

Dr. Mitchell on Survival and Safety of the VELOUR Trial

September 23rd 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.

Merrimack's GI Cancer Agents Show Promise

September 20th 2013

Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.

Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

September 18th 2013

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

First Generic Version of Capecitabine Gains FDA Approval

September 16th 2013

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Dr. Mitchell on Colorectal Cancer Treatment Options

September 10th 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

FDA Approves Nab-Paclitaxel for Advanced Pancreatic Cancer

September 6th 2013

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.